RecruitingPhase 2 / Phase 3NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Sponsor: Mirati Therapeutics Inc.
Alexandria, VA · Arlington, VA · Fairfax, VA · +217 more sites